12
Participants
Start Date
September 7, 2017
Primary Completion Date
October 6, 2017
Study Completion Date
October 30, 2017
Glasdegib Oral Tablet
Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
Glasdegib IV infusion
Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
New Haven Clinical Research Unit, New Haven
Lead Sponsor
Pfizer
INDUSTRY